Neoplasia, Imaging sequences, Computer Applications-General, MR, Neuroradiology brain, MR physics, Molecular imaging
A. Deshmane1, M. Zaiss1, K. Herz1, M. Rivlin2, A. Kujawa3, M. Kim3, G. Navon2, X. Golay3, K. Scheffler1; 1Tuebingen/DE, 2Tel Aviv/IL, 3London/UK
At clinical field strengths,
CEST effects are spectrally broadened and lower in magnitude,
and therefore harder to isolate compared to experiments at ultra-high magnetic field strengths. Translation of CEST imaging to clinical field strengths is therefore challenging. In this study,
a fast 3D snapshot CEST imaging sequence optimized for SNR at 3T was tested for clinical feasibility. For three different pre-saturation types,
snapshot CEST produced consistent contrasts at multiple clinical sites,
with results agreement with previous studies [22,
In addition to showing little contrast between healthy tissue,
the CEST contrast is also stable over time,
which is an important criterion for dynamic studies with injection of a CEST contrast agent such as glucose.
a sophisticated CEST tool with reliable contrast is ready for clinical application.
Larger studies for quantitative assessment of repeatability,
and CEST effect sizes at 3 T in diseased tissues are underway.
We wish to thank Kai Herz at MPI,
Ulrike Ernemann at the University Clinics in Tuebingen for assistance with the tumor patient data.
The financial support of the Max Planck Society,
German Research Foundation (DFG,
grant ZA 814/2-1,
support to M.Z.,
and European Union’s Horizon 2020 research and innovation programme (Grant Agreement No.
support to A.D.,
M.Z.) is gratefully acknowledged.